

of advanced NSCLC were randomized into a treatment group and a control group, with 53 cases in each. The control group adopted systemic chemotherapy, and the treatment group was treated with arterial infusion chemotherapy and oral Chinese herbal decoction. Both groups adopted 3 treatment cycles continuously, with 21 days as one cycle. The body mass and Karnofsky score of patients in each group were measured before and after treatment, and the clinical efficacy and occurrence of adverse reaction induced by chemotherapy were compared. **Results** In the treatment group, there were 2 cases of complete remission (CR), 30 of partial remission (PR), 17 of stable disease (SD) and 4 of progressive disease (PD); the objective response rate (ORR) was 60.38%, and the clinical benefit rate (CBR) was 92.45%. In the control group, the counterparts were 1, 22, 25, 5, 43.40% and 90.57% respectively. The ORR of the treatment group was higher than that of the control group ($P < 0.05$), and there was no statistically significant difference in CBR between the two group ($P > 0.05$). Before and after treatment, there was no statistical significance weight difference in body mass between the two groups ($P > 0.05$). The Karnofsky score in the treatment group after treatment was higher than that before treatment as well as that of the control group after treatment ($P < 0.05$). The adverse reactions in both groups were mainly hair loss, leukocyte decrease, nausea and vomiting. The incidence rate of leukocyte decrease in the treatment group was significantly lower than that in the control group ($P < 0.05$). There were no statistically significant differences in the incidence rates of another two adverse reactions between the two group ($P > 0.05$). **Conclusion** Chinese medicine assisted arterial infusion chemotherapy could improve the quality of life of the patients with advanced NSCLC and reduce the toxic side effects induced by chemotherapy, and its efficacy seems better than systemic chemotherapy alone.

Keywords non-small cell lung cancer; arterial infusion chemotherapy; reinforce spleen and activate blood; quality of life

(收稿日期: 2016-07-11; 修回日期: 2016-07-28)

编辑: 叶 晨

第四届国际中医药临床研究新进展暨养生保健学术大会征文通知

由世界中医药学会联合会国际合作部、《世界中医药》杂志社联合主办的“第四届国际中医药临床研究新进展暨养生保健学术大会”将于 2017 年 5 月 19 日至 22 日在中国福建省泉州市滨海大酒店举行。

一、会议征文与研讨内容: (一) 中医临床及养生保健: (1) 发挥中医特色、继承老中医学术经验的总结; (2) 中医药现代研究的新思路、新方法; (3) 中医、中西医结合临床研究和治疗的新经验、新成果; (4) 中医基础理论研究及探讨; (5) 临床应用成方及验方的治疗体会; (6) 中医食疗及药膳方法介绍及理论研究; (7) 中医养生方法及理论研究; (8) 临床应用推拿、按摩及其它理疗方法的经验; (9) 非药物康复疗法经验总结。

(二) 中药的临床应用及研发与创新: (1) 中药新药的临床研究; (2) 中成药的合理应用; (3) 中西药合并应用的合理性和安全性; (4) 中药临床用药不良反应的分析与防范; (5) 创新药物研发规律与中药制剂创新战略; (6) 中药新药防治疑难病症; (7) 中药复方研究的思路、经验与模式; (8) 中药制剂工艺设计和质量标准化研究; (9) 中药制剂药物动力学与生物等效性的研究。

二、征文要求: (1) 论文要求论点明确、论据充分、结构严密、层次分明、文字精炼, 具有科学性、创新性、实用性; (2) 征文请附医院或主管单位介绍信; (3) 文题下署作者姓名, 作者单位名称、地址、邮政编码、电话请写在文稿末尾, 请在投稿信封左下角注明“会议”字样; (4) 每位作者可投数篇论文(要求 2000 字以内); (5) 征文经专家评审后, 录用文章将刊登在《世界中医药》杂志 2017 年增刊上(第 1、第 2 作者分别授予国家继续教育学分), 并邀请参加会议, 入选论文将安排在大会上交流, 参加会议者颁发证书并授予国家 II 类继续教育 10 学分。征文截止日期为 2017 年 4 月 18 日。

三、会议地址及住宿: 滨海大酒店(四星级) 泉州市丰泽区美桐街中段 28 号(长途中心客运站旁), 电话: 0595 - 22135555。住宿: 双人标间 160 元/床/天; 单人间 270 元/天。

四、注册费用: 国内代表每位 1680 元(含餐费、场地租用费、专家讲课费、会议资料、礼品、会议合影留念、参观交通费); 提前 2 个月回执者优惠 10%。

五、投稿地址: 世界中医药学会联合会国际合作部、《世界中医药》杂志社, 北京市朝阳区小营路 19 号财富嘉园 A 座 303 室, 邮编: 100101, 电话: (010) 58239055、(010) 62143672, 手机: 13901318403, <http://www.wfcm.org>, E-mail: 13901318403@139.com。联系人: 王炳岐、徐晖、邓爱英、赵和爱。

六、汇款方式: 1. 邮局汇款: 收款人: 北京华盛国际医药信息交流中心; 2. 银行汇款: 户名: 北京华盛国际医药信息交流中心, 开户银行: 兴业银行知春路支行, 帐号: 321180100100043563。